-- 据周四提交深圳证券交易所的披露文件显示，吉尔吉斯斯坦药品监管机构已批准河北常山生化药业（深交所代码：300255）的肝素钠注射液上市。 文件指出，该药物用于治疗血栓或栓塞性疾病，具有抗凝血作用，可预防血栓形成。
Related Articles
Asia
Dongjiang Environmental's Loss Widens 2.7% in Q1
Dongjiang Environmental (HKG:0895, SHE:002672) recorded an attributable loss of 150.2 million yuan in the first quarter of 2026, 2.7% wider than 146.3 million yuan a year prior, according to a Monday Hong Kong bourse filing.Loss per share widened to 0.14 yuan from 0.13 yuan in the corresponding period of the previous fiscal year.The waste disposal management company's revenue from operations declined 13% to 602.6 million yuan from 695.9 million yuan in the year-ago period.
$HKG:0895$SHE:002672
Sectors
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Health care stocks were edging higher pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) marginally advancing.Organon (OGN) has agreed to be acquired by Sun Pharmaceutical Industries for $14 per share in an all-cash deal with an $11.75 billion enterprise valuation, the companies said. Shares of Organon were up more than 17% premarket.Oruka Therapeutics (ORKA) stock was up more than 34% after the company said 63.5% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.Ligand Pharmaceuticals (LGND) shares were up more than 3% after the company said it has agreed to purchase biotechnology peer Xoma Royalty (XOMA) in an all-cash deal valued at roughly $739 million.
$IBB$LGND$OGN$ORKA$XLV$XOMA
Asia
Zuoli Kechuang Logs Drop in Q1 Profit
Zuoli Kechuang Micro-finance Company (HKG:6866) recorded a decline in attributable profit in the first quarter of 2026 to 13.6 million yuan from 14.8 million yuan a year prior, according to a Monday Hong Kong bourse filing.Net interest income for the three months slipped to 28.4 million yuan from 35.2 million yuan in the year-ago period.
$HKG:6866